Rotavirus Vaccines Clinical Trial
Official title:
Using "Decision Aids" to Help the Infant Family to Decide Whether the Baby Will Receive the Self-paid Oral Rotavirus Vaccine: A Randomized Controlled Trial.
Using decision aids (DA) is one way to provide information to infant family and to involve them in making decisions about their baby's vaccination. We developed a DA administered after consultation for baby's family deciding on whether the baby will receive the self-paid oral rotavirus vaccine
Status | Not yet recruiting |
Enrollment | 180 |
Est. completion date | December 25, 2019 |
Est. primary completion date | October 25, 2019 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 20 Years to 80 Years |
Eligibility |
Inclusion Criteria: The one-month-old baby's family whose age is between 20 and 80 years old. Exclusion Criteria: 1. . The doctor determines that the baby's family is not suitable; if baby's family cannot understand Chinese languages what we said. 2. . The participants' baby who have fever or contraindication for oral rotavirus. |
Country | Name | City | State |
---|---|---|---|
Taiwan | Sheng-Chieh Lin | New Taipei City | No.291, Zhongzheng Road, Zhonghe District, New Taipei City |
Lead Sponsor | Collaborator |
---|---|
Taipei Medical University Shuang Ho Hospital |
Taiwan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Decisional conflict | Total score of decisional conflict scale | An average of 1 month after intervention | |
Primary | Decision-making difficulties | Total score of decision-making scale | An average of 1 month after intervention |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03207750 -
This Study Will Evaluate the Immunogenicity, Reactogenicity and Safety of the Routine Infant Vaccines Pediarix®, Hiberix® and Prevenar 13® When Co-administered With GlaxoSmithKline (GSK) Biologicals' Liquid Human Rotavirus Vaccine (HRV) as Compared to GSK's Licensed Lyophilized Vaccine
|
Phase 3 | |
Completed |
NCT02914184 -
Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
|
Phase 3 | |
Completed |
NCT00241644 -
Vaccine Efficacy Against Rotavirus Diarrhea; Vaccine Given With Routine Childhood Vaccinations in Healthy African Infants
|
Phase 3 | |
Completed |
NCT01733862 -
Study to Assess the Impact of Vaccination on Hospitalizations and Outpatient Visits Due to Rotavirus Gastroenteritis
|
||
Completed |
NCT00353366 -
To Evaluate Safety & Reactogenicity of GSK Bio's Human Rotavirus (HRV) Vaccine in Filipino Infants at Least 6 Weeks of Age at First Vaccination
|
||
Unknown status |
NCT00669929 -
Cost-Effectiveness Analysis of Rotavirus Vaccination for Children in Korea
|
N/A | |
Completed |
NCT00432380 -
A Study to Evaluate Immune Response and Safety of Two Doses of GSK Biologicals' HRV Liquid Vaccine in Healthy Infants.
|
Phase 2 | |
Completed |
NCT05037435 -
Safety and Immunological Efficacy of the Pentavalent Rotavirus Vaccine - Rota-V-Aid™ (Live Attenuated Oral, Freeze-dried) at Healthy Adults Aged 18 to 45 Years.
|
Phase 3 | |
Completed |
NCT00480324 -
Efficacy, Safety, Reactogenicity & Immunogenicity of the Rotarix Vaccine in Japanese Infants
|
Phase 3 | |
Completed |
NCT00595205 -
Intussusception Surveillance After Rotarix Introduction in Mexico
|
N/A | |
Completed |
NCT01177826 -
Effectiveness Study of GSK Biologicals' Rotarix TM Vaccine in Hospitalized Children
|
||
Completed |
NCT00995813 -
Pilot Study of the Rotavirus Vaccine in Infants With Intestinal Failure
|
Phase 4 | |
Completed |
NCT00969228 -
Study to Evaluate Immunogenicity, Reactogenicity and Safety of Rotarix™ Vaccine in Korean Infants
|
Phase 4 |